Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 6:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 223 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Metformin + Insulin Clear all
Not listed Phase 4 Interventional

Evaluation of the Impact of Intensive Short-Term Drug Therapy in Patients With Type 2 Diabetes Mellitus

NCT04027023
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Diabetes mellitus Type 2 De-escalation treatment (DET)
Drug
Lead sponsor
Sciema UG
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Oct 3, 2026, 6:54 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study of Serum Markers for Cardiovascular Risk in Obese Youth and Impact of Lifestyle and Medication Intervention

NCT00139477
View directory record Official record
Conditions
Obesity
Interventions
Metformin, Dietary modification with caloric restriction, Establishment of exercise protocol
Drug · Behavioral
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
7 Years to 18 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2011
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 3, 2026, 6:54 PM EDT
Completed Phase 2 Interventional Results available

Exercise and Metformin in Colorectal and Breast Cancer Survivors

NCT01340300
View directory record Official record
Conditions
Colorectal Cancer, Breast Cancer
Interventions
Exercise training, Metformin, Educational information
Behavioral · Drug · Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
2
States / cities
New Haven, Connecticut • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 3, 2026, 6:54 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

How Glargine Insulin, Oral Diabetes Medications and Exenatide May Improve Blood Sugar Control and Weight Gain in Type 2 Diabetics

NCT00667732
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
exenatide, placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
30 Years to 70 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Rochester, Minnesota • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 6, 2013 · Synced Oct 3, 2026, 6:54 PM EDT
Completed Not applicable Interventional

Developing an Adaptive Lifestyle Intervention Program in Family Medicine Clinics

NCT04392284
View directory record Official record
Conditions
Insulin Resistance, Obesity, Diabetes, Hypertension, Dyslipidemias, Metabolic Syndrome
Interventions
Diet Counseling, Exercise Counseling
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Oct 3, 2026, 6:54 PM EDT
Completed Phase 4 Interventional Results available

Metabolic Abnormalities in HIV-infected Persons

NCT01612858
View directory record Official record
Conditions
Lipodystrophy, HIV Infection
Interventions
Metformin, Pioglitazone
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 20, 2016 · Synced Oct 3, 2026, 6:54 PM EDT
Completed Phase 3 Interventional Results available

A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes

NCT04596631
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Oral semaglutide, Placebo (semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
10 Years to 18 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
23
States / cities
Birmingham, Alabama • Los Angeles, California • New Haven, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 3, 2026, 6:54 PM EDT
Completed Phase 2 Interventional Results available

Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes

NCT02597101
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Insulin Resistance
Interventions
Metformin, saxagliptin, AZD9668, placebo
Drug
Lead sponsor
Nick Giannoukakis, PhD
Other
Eligibility
21 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 3, 2026, 6:54 PM EDT
Completed Phase 4 Interventional Results available

Metformin for Overweight & OBese ChILdren and Adolescents With BDS Treated With SGAs

NCT02515773
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Metformin, healthy lifestyle intervention (LIFE)
Drug · Behavioral
Lead sponsor
Melissa Delbello
Other
Eligibility
8 Years to 19 Years
Enrollment
1,565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
29
States / cities
Covington, Kentucky • Neptune City, New Jersey • Amityville, New York + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 3, 2026, 6:54 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Type 2 Diabetes

NCT00605475
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Canakinumab, Placebo, Metformin
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
6
States / cities
Little Rock, Arkansas • Miami, Florida • MD, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2012 · Synced Oct 3, 2026, 6:54 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes

NCT01023581
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Alogliptin, Metformin, Alogliptin Placebo, Metformin Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
784 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
109
States / cities
Dothan, Alabama • Muscle Shoals, Alabama • Pell City, Alabama + 106 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2013 · Synced Oct 3, 2026, 6:54 PM EDT
Completed Not applicable Interventional Results available

The Synergy to Control Emergency Department Hyperglycemia Program for Type 2 Diabetes

NCT02269098
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Medication Adherence, HYPERGLYCEMIA
Interventions
Diabetes medication management
Other
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 3, 2026, 6:54 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes

NCT02058160
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Insulin glargine/lixisenatide (HOE901/AVE0010), Insulin glargine (HOE901), Metformin (Background Drug)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
736 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
108
States / cities
Birmingham, Alabama • Sun City, Arizona • Tempe, Arizona + 91 more
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 3, 2026, 6:54 PM EDT
Terminated Phase 3 Interventional Results available

Effect of Weight and Insulin Sensitivity on Reproductive Function in PCOS

NCT01482286
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Metformin, Dietary Restriction, Exercise Training
Drug · Behavioral
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
20 Years to 40 Years · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Oct 3, 2026, 6:54 PM EDT
Terminated Phase 4 Interventional Results available

Oral Anti Diabetic Agents in the Hospital

NCT04416269
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Oral Anti-diabetes Drugs alone, Basal bolus insulin, Supplemental insulin, Continuous glucose monitoring (CGM)
Drug · Device
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 3, 2026, 6:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.

NCT03169959
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
2.5 mg Saxagliptin tablet, 5 mg dapagliflozin / 1000 mg metformin XR tablet, Triple FCDP - 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR, 5 mg saxagliptin, 10 mg dapagliflozin / 1000 mg metformin XR tablet, Triple FCDP - 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 14, 2017 · Synced Oct 3, 2026, 6:54 PM EDT
Active, not recruiting No phase listed Observational

Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study

NCT05220917
View directory record Official record
Conditions
Cardiovascular Events, Type2 Diabetes, Renal Disease
Interventions
SGLT2 inhibitor, DPP-4 inhibitor, GLP-1RA, 2nd generation SU
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
781,430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 3, 2026, 6:54 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

QR-Bromocriptine as an Adjunct to Insulin and Metformin in the Treatment of Type 2 Diabetes

NCT01474018
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
QR-bromocriptine
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
30 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Oct 3, 2026, 6:54 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Pilot Study of BMS-512148 in Subjects With Type 2 Diabetes

NCT00357370
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
16
States / cities
Jonesboro, Arkansas • Fresno, California • Greenbrae, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Oct 3, 2026, 6:54 PM EDT
Completed Phase 3 Interventional

Comparison of Biphasic Insulin Aspart 70/30 With Anti-Diabetic Drugs in Subjects With Type 2 Diabetes

NCT00097279
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
biphasic insulin aspart, pioglitazone, metformin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
73
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 3, 2026, 6:54 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Saxagliptin Plus Insulin With or Without Metformin

NCT00757588
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Saxagliptin, 5 mg + insulin, Placebo + insulin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 78 Years
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
16
States / cities
Tempe, Arizona • Fresno, California • Lomita, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Oct 3, 2026, 6:54 PM EDT
Completed Phase 3 Interventional

Evaluate the Role of Adding Amaryl to Non-Insulin Dependent Diabetes Mellitus Patients Unresponsive to Maximum Dose Metformin & Thiazolidinedione

NCT00044447
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
Glimepiride
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 19, 2008 · Synced Oct 3, 2026, 6:54 PM EDT
Terminated Phase 3 Interventional

A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus

NCT04754334
View directory record Official record
Conditions
T2DM (Type 2 Diabetes Mellitus)
Interventions
ORMD-0801, Placebo
Drug · Other
Lead sponsor
Oramed, Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 3, 2026, 6:54 PM EDT
Completed Phase 4 Interventional Results available

Adding an Insulin-Sensitizing Medication to Depression Treatment for People Who Are Depressed and Overweight

NCT00834652
View directory record Official record
Conditions
Depression
Interventions
Sertraline, Metformin
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
20 Years to 60 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 3, 2026, 6:54 PM EDT